ES2683042T3 - Tratamiento de síntomas asociados a la gastroparesia en mujeres - Google Patents

Tratamiento de síntomas asociados a la gastroparesia en mujeres Download PDF

Info

Publication number
ES2683042T3
ES2683042T3 ES12825447.1T ES12825447T ES2683042T3 ES 2683042 T3 ES2683042 T3 ES 2683042T3 ES 12825447 T ES12825447 T ES 12825447T ES 2683042 T3 ES2683042 T3 ES 2683042T3
Authority
ES
Spain
Prior art keywords
metoclopramide
treatment
gastroparesis
composition
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12825447.1T
Other languages
English (en)
Spanish (es)
Inventor
Matthew J. D'onofrio
David A. Gonyer
Marilyn R. Carlson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evoke Pharma Inc
Original Assignee
Evoke Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evoke Pharma Inc filed Critical Evoke Pharma Inc
Application granted granted Critical
Publication of ES2683042T3 publication Critical patent/ES2683042T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES12825447.1T 2011-08-25 2012-08-23 Tratamiento de síntomas asociados a la gastroparesia en mujeres Active ES2683042T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161527563P 2011-08-25 2011-08-25
US201161527563P 2011-08-25
US201261583447P 2012-01-05 2012-01-05
US201261583447P 2012-01-05
PCT/US2012/052096 WO2013028882A1 (en) 2011-08-25 2012-08-23 Treatment of symptoms associated with female gastroparesis

Publications (1)

Publication Number Publication Date
ES2683042T3 true ES2683042T3 (es) 2018-09-24

Family

ID=47746868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12825447.1T Active ES2683042T3 (es) 2011-08-25 2012-08-23 Tratamiento de síntomas asociados a la gastroparesia en mujeres

Country Status (14)

Country Link
US (1) US20130217775A1 (https=)
EP (1) EP2747561B1 (https=)
JP (3) JP2014524478A (https=)
CN (1) CN103957707A (https=)
BR (1) BR112014004418A8 (https=)
CA (1) CA2846340A1 (https=)
DK (1) DK2747561T3 (https=)
ES (1) ES2683042T3 (https=)
MX (1) MX356317B (https=)
PL (1) PL2747561T3 (https=)
PT (1) PT2747561T (https=)
RU (1) RU2616520C2 (https=)
TR (1) TR201811221T4 (https=)
WO (1) WO2013028882A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
EP3554489A4 (en) 2016-12-15 2020-06-17 Evoke Pharma, Inc. TREATMENT FROM MODERATE TO HEAVY GASTROPARESIS
WO2018191584A1 (en) * 2017-04-14 2018-10-18 The Johns Hopkins University Nutritional and therapeutic supplement compositions
KR102692887B1 (ko) * 2017-07-31 2024-08-08 알파시그마 에스.피.에이. 벨루세트라그를 사용하여 위마비 증상을 치료하는 방법
EP3681573A4 (en) * 2017-09-11 2021-08-04 Evoke Pharma, Inc. METOCLOPRAMIDE METHOD OF DOSING INTRANASAL METOCLOPRAMIDE
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL281394A (https=) 1961-07-25
US4624965A (en) 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US5760086A (en) 1996-03-14 1998-06-02 Ribogene, Inc. Nasal administration of agents for treatment of delayed onset emesis
HUP9902891A3 (en) * 1997-03-13 2000-11-28 Ribogene Inc Hayward Intranasal administration of a metoclopramide containing spray for treatment of delayed onset emesis
US6187332B1 (en) * 1999-06-14 2001-02-13 Wisconsin Alumni Research Foundation Acidic buffered nasal spray
GB9918559D0 (en) * 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
US6770262B2 (en) * 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
US20030044356A1 (en) * 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20050137265A1 (en) * 2003-03-31 2005-06-23 Haley Eugene T. Rapidly dissolving metoclopramide solid oral dosage and method thereof
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
PL2376075T3 (pl) 2008-12-22 2015-08-31 Evoke Pharma Inc Donosowe preparaty z metoklopramidu
JP2012521412A (ja) * 2009-03-23 2012-09-13 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． 鼻のアレルギー疾患において適用するためのクルクミノイドおよびその代謝物

Also Published As

Publication number Publication date
EP2747561A1 (en) 2014-07-02
JP6511492B2 (ja) 2019-05-15
PL2747561T3 (pl) 2018-11-30
EP2747561B1 (en) 2018-05-09
EP2747561A4 (en) 2014-12-24
CN103957707A (zh) 2014-07-30
TR201811221T4 (tr) 2018-08-27
MX356317B (es) 2018-05-23
BR112014004418A8 (pt) 2018-01-23
PT2747561T (pt) 2018-09-28
BR112014004418A2 (pt) 2017-03-28
DK2747561T3 (en) 2018-08-06
RU2616520C2 (ru) 2017-04-17
JP2014524478A (ja) 2014-09-22
MX2014002125A (es) 2014-10-17
CA2846340A1 (en) 2013-02-28
WO2013028882A1 (en) 2013-02-28
RU2014111070A (ru) 2015-09-27
JP2018008979A (ja) 2018-01-18
JP2019031551A (ja) 2019-02-28
US20130217775A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
ES2760251T3 (es) Método para el tratamiento de trastorno de estrés postraumático
ES2683042T3 (es) Tratamiento de síntomas asociados a la gastroparesia en mujeres
Boateng Drug delivery innovations to address global health challenges for pediatric and geriatric populations (through improvements in patient compliance)
ES2635137T3 (es) Formas de dosificación oral transmucosal que comprenden sufentanilo y triazolam
ES2355399T3 (es) Soluciones concentradas de metotrexato.
US20220151960A1 (en) Treatment of symptoms associated with female gastroparesis
ES2709849T3 (es) Uso de levocetirizina y montelukast en el tratamiento de anafilaxia
US12377064B2 (en) Treatment of moderate and severe gastroparesis
ES2749800T3 (es) Formulación de liberación sostenida de naltrexona
ES2401269B1 (es) Composiciones para su uso en el tratamiento y/o prevención del cáncer colorrectal
ES2346290T3 (es) Administracion nasal de metoclopramida para el tratamiento de gastroparesia.
ES2694506T3 (es) Administración de ibuprofeno por vía intravenosa
ES2692345T5 (es) Administración intranasal de desmopresina
ES2398960T3 (es) Composición farmacéutica novedosa y su uso en un método para el tratamiento de pacientes con cangestión mucosa de las vías respiratorias altas
US20040192781A1 (en) Method of administration for metoclopramide and pharmaceutical formulation therefor
EP4218750A1 (en) The use of melanin in therapy of subjects with trisomy 21
COPPARD et al. Use of Medications by Older Adults
JP2004210750A (ja) 生体リズム応用キット
Kerr et al. Intranasal diamorphine usage in paediatric accident and emergency
BR8300543U (pt) Embalagem, ou kit de medicamentos, ou apresentação facilitadora da administração de medicamentos por parte dos pacientes
POTENSYL SMMSMSMSMS SS
Ciappara Drug therapy in the elderly
Gever Drug challenge
NO et al. BUF F ERIN
WARD BHILBLAINS & COUGHS